| answer text |
<p>The agreement of an implementation period will ensure that access to medicines
and medical devices continues, and patient safety is maintained, in both the United
Kingdom and European Union markets.</p><p> </p><p>The Medicines and Healthcare products
Regulatory Agency (MHRA) will continue to be the UK competent authority during this
period.</p><p> </p><p>For medical devices, CE marks are assigned by notified bodies
(rather than competent authorities such as the MHRA), and during the implementation
period UK notified bodies will continue to conduct third-party conformity assessment
in the UK, and the results of these tests will continue to be used and recognised
for both the UK and EU markets.</p>
|
 |
